HOME
PRODUCTS
SERVICES
COMPANY
CONTACT
FAQ
Research
Dictionary
Pharma
Mobile
Sign Up
FREE
or
Login
Username:
Password:
Remember login
Login
Send password reminder...
piretanide
Subscribe to New Research on piretanide
potent inhibitor of chloride transport; structure
Also Known As:
4-phenoxy-3-pyrrolidin-1-yl-5-sulfamoylbenzoic acid; HOE 118
Networked:
81
relevant articles (
16
outcomes,
21
trials/studies)
Relationship Network
Bio-Agent Context: Research Results
Organic Chemicals: 58
Amides: 231
Sulfonamides: 931
piretanide: 81
Sulfur Compounds: 135
Sulfones: 136
Sulfonamides: 931
piretanide: 81
Related Diseases
1.
Heart Failure
04/01/1990 - "
Thus, the diuretic monotherapy of congestive heart failure with piretanide is highly effective and shows a significant improvement in all clinical and hemodynamic parameters in the absence of any remarkable side effects.
"
08/01/1989 - "
Thus patients with congestive heart failure exhibit a decreased renal clearance of piretanide and a good response to this high ceiling diuretic after intravenous dosing.
"
06/15/1989 - "
In patients with acute decompensated heart failure (group 2) piretanide led to a significant reduction in mean pulmonary artery pressure (from 42 +/- 13 to 37 +/- 12 mm Hg; p less than 0.05) within 15 minutes after administration, i.e.
"
08/01/1988 - "
Piretanide was well tolerated, and effective in the management of congestive cardiac failure without any other recognized metabolic or electrolyte changes.
"
08/01/1989 - "
When compared with another group of healthy volunteers, patients with congestive heart failure had reduced total body clearance of piretanide of about 50% which was attributable to a diminished renal but not non-renal clearance.
"
2.
Hypertension (High Blood Pressure)
01/01/1989 - "
2. Piretanide (30 mg/kg) prevented development of hypertension and produced a significant reduction in blood pressure from the 2nd week of the treatment.
"
01/01/1986 - "
In a randomized, double-blind parallel group study the 24-hour hypotensive effect of piretanide and its influence on biochemical variables were compared with those of placebo in patients with mild to moderate essential hypertension.
"
01/01/1985 - "
In a randomized double-blind parallel group study the effects of two formulations of piretanide (standard tablet and slow-release capsule) were compared in patients with mild to moderate essential hypertension.
"
01/01/1983 - "
A double-blind trial was carried out in three parallel groups of patients with mild to moderate hypertension to assess the efficacy and tolerance of piretanide given as a single dose of 3 mg, 6 mg or 12 mg per day over a period of 12 weeks.
"
10/31/1986 - "
The effect of antihypertensive treatment with 6-12 mg of the loop diuretic piretanide over 12 weeks on Na+-Li+ countertransport, and on extra- and intracellular electrolyte composition was studied in 10 previously untreated patients with essential hypertension.
"
3.
Renal Insufficiency (Renal Failure)
01/01/1983 - "
Piretanide appeared to be effective in advanced renal insufficiency.
"
01/01/1988 - "
Multiple daily doses of piretanide of maximally 24 mg are recommended for optimal efficiency in renal failure.
"
01/01/1985 - "
The present data suggest that single daily doses of piretanide will not result in accumulation, even when high doses are administered to patients with advanced renal failure.
"
01/01/1985 - "
Because the diuretic effect of piretanide depends on the concentration of the drug in the tubule, the observed correlation might be of use in evaluating the appropriate dosage of piretanide in patients with renal failure.
"
01/01/1985 - "
Piretanide 60 mg was administered intravenously over 30 min to 15 men with different degrees of renal failure.
"
4.
Asthma (Bronchial Asthma)
07/01/1993 - "
These data indicate that inhaled piretanide is as effective as furosemide in preventing UNW-induced asthma, and this effect is unrelated to their diuretic potency.
"
07/01/1993 - "
To verify whether this protective effect is also shared by other loop diuretics, we investigated the effect of inhaled piretanide on the bronchial obstructive response to ultrasonically nebulized distilled water (UNW) in ten patients with moderate, stable asthma.
"
11/01/1992 - "
Protective effect of loop diuretics, piretanide and frusemide, against sodium metabisulphite-induced bronchoconstriction in asthma.
"
5.
Ascites
01/01/1985 - "
Reduced responsiveness to piretanide therapy in patients with gross ascites does not appear to be the result of decreased bioavailability.
"
01/01/1985 - "
The influence of ascites on the pharmacokinetics of piretanide in cirrhotic patients.
"
01/01/1985 - "
The pharmacokinetics of piretanide, a new loop diuretic, were studied in seven patients with severe liver disease before and after resolution of ascites.
"
10/01/1980 - "
Use of piretanide, a new loop diuretic, in cirrhosis with ascites: relationship between the diuretic response and the plasma aldosterone level.
"
01/01/1985 - "
In the first study, they compared bumetanide and piretanide by the method of compensated diuresis; in the second, they tested the three loop diuretics' efficacy in refractory ascites.
"
Related Drugs and Biologics
1.
Penbutolol
2.
Furosemide (Lasix)
3.
Potassium
4.
Triamterene (Dyrenium)
5.
Creatinine
6.
Uric Acid (Urate)
7.
Urea (Carbamide)
8.
Sodium Chloride (Saline Solution)
9.
Inulin
10.
Calcium
Related Therapies and Procedures
1.
Oral Administration